Kala Pharmaceuticals - KALA Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALA, but not buy additional shares or sell existing shares.
View KALA analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year target prices for Kala Pharmaceuticals' shares. Their KALA share price forecasts range from $0.75 to $2.00. On average, they anticipate the company's stock price to reach $1.38 in the next twelve months. This suggests a possible upside of 443.9% from the stock's current price.
View analysts price targets for KALA or view top-rated stocks among Wall Street analysts.

Kala Pharmaceuticals' stock was trading at $0.6050 at the beginning of 2022. Since then, KALA stock has decreased by 58.2% and is now trading at $0.2528.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our KALA earnings forecast.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) issued its earnings results on Thursday, August, 11th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.06. The business earned $2.10 million during the quarter, compared to the consensus estimate of $2.57 million. Kala Pharmaceuticals had a negative trailing twelve-month return on equity of 1,320.11% and a negative net margin of 1,628.91%.

Kala Pharmaceuticals's stock split on the morning of Friday, August 26th 2022. The 2-1 split was announced on Friday, August 26th 2022. The newly minted shares were distributed to shareholders after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

1 employees have rated Kala Pharmaceuticals Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.79%), Renaissance Technologies LLC (0.49%), State Street Corp (0.36%), Goldman Sachs Group Inc. (0.33%), Vahanian & Associates Financial Planning Inc. (0.25%) and Integrated Wealth Concepts LLC (0.21%). Insiders that own company stock include Eric Trachtenberg, Hongming Chen, Mark T Iwicki, Mark T Iwicki, Mary Reumuth, Ra Capital Management, LP, Rajeev M Shah, Romulus K Brazzell and Todd Bazemore.
View institutional ownership trends.

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KALA stock can currently be purchased for approximately $0.25.

Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $18.51 million and generates $11.24 million in revenue each year. The company earns $-142,600,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.

The company employs 192 workers across the globe.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for the company is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399.